Particularly, the small molecule inhibitor palbociclib, targeting CDK4/6, exhibited notable anti-tumor effects in various B-cell lymphoma cell lines, while also activating the PI3K-AKT pathway. Combining CDK4/6 inhibitors with PI3K inhibitors demonstrated a synergistic anti-B cell lymphoma effect ...
Phosphoinositide 3-kinase inhibitorTreatmentOpinion statement: Phosphatidylinositol 3-kinase (PI3K) inhibitors represent a novel class of agents targeting the key cellular regulatory PI3K/AKT/mTOR pathway involved in crucial functions such as cellular proliferation, cell cycle regulation, protein synthesis, ...
AKTinhibitor(MK-2206). Conclusions WeusedneonatalmousecochlearCortiorganandHEI-OC1cellsasthemodels andconfirmedthatCinchonineandCinchonidinecanreducecisplatin-induced apoptosisandmitochondrialoxidativestressinneonatalmouseCortiorganand HEI-OC1cellsinvitroviaPI3K/AKTpathway,thusreducingcisplatin-induced ototoxicityandultim...
7G. To determine whether the autophagy-lysosome pathway participates in the regulation of G6PD under exposure to PI3K/mTOR inhibitors, chloroquine (CQ), an autophagy inhibitor, was combined with IR and PI3K/mTOR inhibitors. BEZ235/GSK2126458 could promote the degradation of G6PD protein mediated by...
lisib (Bez235), voxtalisib (XL765) and GSK1059615.30Although this type of inhibitor is less specific than isotype-specific inhibitors, it has the potential to treat a variety of tumors with a wide range of genetic abnormalities; however, it also has many unknown toxicities and side effects....
CAL-101 (GS-1101, idelalisib) is an oral and specific inhibitor of the δ isoform of PI3K [122,123]. It has been shown that idelalisib has therapeutic effects without inhibiting PI3K signaling essential for normal function of healthy cells [157,158]. Idelalisib is the frst FDA-approved PI3K...
lisib (Bez235), voxtalisib (XL765) and GSK1059615.30Although this type of inhibitor is less specific than isotype-specific inhibitors, it has the potential to treat a variety of tumors with a wide range of genetic abnormalities; however, it also has many unknown toxicities and side effects....
efficacy than the first-generation PI3Kδ inhibitor Idelalisib without showing obvious renal or hepatoxicity in vivo (Fig.3). Further experiments are needed to clarify the safety profile of TYM-3-98, for example, evaluating the side effects commonly associated with δ isoform such as ...
Importantly, our group and others have shown promising anti-tumor effects on MCC by inhibition of PI3K and mTOR26,27,47,49,58,59. Recently we first reported PI3K-δ expression in human MCC cells and the first successful clinical application of PI3K-δ inhibitor in a Stage IV MCC patient ...
In addition, LY294002 and BI2536 (an inhibitor of Plk1), together with gemcitabine significantly suppressed the growth of xenografts in nude mice model, which made PI3K/Akt pathway inhibition as well as Plk1 down-regulation become a potential target to increase the chemosensitivity of PC. ...